An interventional study of Labetalol and Phentolamine in Severe Pre-eclampsia, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-04-26.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing labetalol in Pre-Eclampsia — 5 open to participants now, 6 under way, 2 of them phase 3. Labetalol · Pre-Eclampsia.
Among the 16 studies testing labetalol in Pre-Eclampsia, this one is the 7th largest by planned enrollment, is one of 4 that started in 2024, is one of 4 with no phase, and was the 12th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 245 are open to participants now.
Browse Pre-Eclampsia studies →5 of the 16 studies testing labetalol in Pre-Eclampsia are open now, in 2 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 25–45 · Women only
Nebraska Methodist Health System · Sites in United States
Ages 19+ · Women only
The George Washington University Biostatistics Center · Sites in United States
Ages 14–56 · Women only · Healthy volunteers
Sohag University
Ages 18–40 · Women only
By country, each count listing its studies:
Labetalol: first FDA approval 1984 (NORMODYNE). What it is approved for, and how studies give it, is on its page →
Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3 · Phase 4 5
First in 2012; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 161 across the 16 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
31 studies in Pre-Eclampsia by Assiut University: 6 open now, 6 under way, none of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 31 studies in Pre-Eclampsia by Assiut University, this one is the 4th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2024, is one of 6 with no phase, and was the 25th registered.
Assiut University’s Pre-Eclampsia studies by the year they started, since 2016.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing labetalol in Pre-Eclampsia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Assiut University’s 31 in Pre-Eclampsia:
This tab as a report to print or save as PDF → With an account.
The only effective treatment of severe preeclampsia is delivery of the fetus but immediate antihypertensive treatment is given to stabilize the patient and prevent further complications. All antihypertensive medication can potentially cross the placenta. At this time, there are no randomized control trials to base a recommendation for the use of one antihypertensive agent over another. However, certain medications are effective in lowering blood pressure with an acceptable safety profile in pregnancy. The choice of therapy depends on the acuity and severity of hypertension
Non-invasive assessment of cerebral haemodynamics using Transcranial doppler ultrasonography has recently gained importance. Essentially, TCD measures flow velocity in the insonated vessel and the changes in flow velocity can be taken to reflect the changes in blood flow, assuming that the diameter of the insonated vessel remains constant. As TCD is easy to use and gives reproducible measurements, it has become a widely accepted method of assessing the cerebrovascular reactivity to carbon dioxide (CRCO2), cerebral autoregulation, estimated CPP, and CrCP. In patients with neurological disorders, impairment in both cerebral autoregulation and cerebral vascular reactivity has been shown to predict poor neurological outcome. Knowledge of the effects of normal pregnancy and pre-eclampsia on cerebral haemodynamics is essential for appropriate management of these patients undergoing anaesthesia or in labour, particularly when vasoactive medications are administered. The effects of pregnancy and/or pre-eclampsia on MCAFV have been studied by other investigators. Ikeda and colleagues found little change in mean MCAFV during the first two trimesters but reduced values in the third trimester. Williams and Wilson showed that MCAFV fell significantly with advancing gestational age. In another study, Williams and Wilson used TCD to assess cerebral haemodynamics in 17 non-pregnant women, 17 normotensive pregnant women, 20 pregnant women with pre-existing hypertension, and 21 pre-eclamptic women. The pregnant women were all in their third trimester. There was no difference in mean MCAFV in healthy pregnancy compared with non-pregnant women and a small, but non-significant, increase in mean MCAFV in the hypertensive and pre-eclamptic women. Demarin and colleagues studied pre-eclamptic women before and after delivery and found a progressive increase in MCAFV during late pregnancy. Ohno and colleagues compared MCAFV in 35 healthy pregnant and 17 pre-eclamptic women. In this study, the mean MCAFV was significantly higher in the pre-eclamptic group. It has been suggested that these increases in MCAFV are because of a degree of vasospasm. The differences between the findings of various studies with regards to the changes in MCAFV in pre-eclampsia might be explained by the differences in the severity of pre-eclampsia between the studies. Some investigators have reported increased MCAFV in symptomatic, compared with asymptomatic pre-eclamptics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pregnant woman with severe preeclampsia diagnosed by obstetric doctor
Exclusion Criteria:
Patients with eminent eclampsia
labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient
Drug: Labetalol
phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient
Drug: Phentolamine
Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
Also known as: trandate, Gsk
Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
Also known as: Rogitamine
the effect of Labetalol and Phentolamine on MCA flow velocity by transcranial Doppler monitoring.
Singleton pregnant women who suffered from late onset preeclampsia will be enrolled and subjected to baseline Transcranial doppler (TCD) evaluation to measure middle cerebral artery (MCA) blood flow indices including mean flow velocity (cm/s).
Time frame: 6 hours
The effect of labetalol and phentolamine on blood pressure of the patients
through measuring the blood pressure in (mmHg)
Time frame: 6 hours
No study locations are listed for this record.
Start is estimated for May 2024; primary completion for Jan 2026, 20 months later.
Of 171 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 20 months is below that.
Counting every sponsor, half of 176 studies reached it within 24 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Labetalol · Phentolamine